As of 2024-09-14, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -2.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 275.12 mil USD. KPTI's TTM EBITDA according to its financial statements is -116.27 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 16.8x | 13.9x |
| Forward P/E multiples | 15.5x - 21.7x | 18.1x |
| Fair Price | (15.92) - (17.15) | (16.36) |
| Upside | -2182.9% - -2344.0% | -2241.5% |
| Date | EV/EBITDA |
| 2024-09-13 | -2.37 |
| 2024-09-12 | -2.34 |
| 2024-09-11 | -2.34 |
| 2024-09-10 | -2.32 |
| 2024-09-09 | -2.34 |
| 2024-09-06 | -2.33 |
| 2024-09-05 | -2.40 |
| 2024-09-04 | -2.31 |
| 2024-09-03 | -2.32 |
| 2024-08-30 | -2.36 |
| 2024-08-29 | -2.37 |
| 2024-08-28 | -2.39 |
| 2024-08-27 | -2.40 |
| 2024-08-26 | -2.43 |
| 2024-08-23 | -2.44 |
| 2024-08-22 | -2.39 |
| 2024-08-21 | -2.41 |
| 2024-08-20 | -2.39 |
| 2024-08-19 | -2.42 |
| 2024-08-16 | -2.42 |
| 2024-08-15 | -2.44 |
| 2024-08-14 | -2.41 |
| 2024-08-13 | -2.44 |
| 2024-08-12 | -2.42 |
| 2024-08-09 | -2.42 |
| 2024-08-08 | -2.45 |
| 2024-08-07 | -2.42 |
| 2024-08-06 | -2.45 |
| 2024-08-05 | -2.48 |
| 2024-08-02 | -2.50 |
| 2024-08-01 | -2.54 |
| 2024-07-31 | -2.61 |
| 2024-07-30 | -2.68 |
| 2024-07-29 | -2.65 |
| 2024-07-26 | -2.59 |
| 2024-07-25 | -2.58 |
| 2024-07-24 | -2.56 |
| 2024-07-23 | -2.54 |
| 2024-07-22 | -2.52 |
| 2024-07-19 | -2.50 |
| 2024-07-18 | -2.53 |
| 2024-07-17 | -2.60 |
| 2024-07-16 | -2.62 |
| 2024-07-15 | -2.59 |
| 2024-07-12 | -2.56 |
| 2024-07-11 | -2.58 |
| 2024-07-10 | -2.48 |
| 2024-07-09 | -2.45 |
| 2024-07-08 | -2.39 |
| 2024-07-05 | -2.42 |